Evidence map›Paper›PMID 41029387›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

DUSP8 as a regulator of glioblastoma stem-like cell contribution to tumor vascularization.

Giorgia Castellani, Mariachiara Buccarelli, Quintino Giorgio D'Alessandris, Gabriele De Luca, Ramona Ilari, Francesca Pedini, Maurizio Martini, Cristiana Mollinari, Claudio Tabolacci, Gabriele Ricciardi and 7 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Giorgia Castellani *Department of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Mariachiara Buccarelli *Department of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Quintino Giorgio D'AlessandrisDepartment of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. quintinogiorgio.dalessandris@unicatt.it.
Gabriele De LucaDepartment of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Ramona IlariDepartment of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Francesca PediniDepartment of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Maurizio MartiniDepartment of Human Pathology of Adult and Developmental Age, "Gaetano Barresi", Division of Pathology, Messina, Italy.
Cristiana MollinariDepartment of Neuroscience, Istituto Superiore Di Sanita', Rome, Italy.
Claudio TabolacciDepartment of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Gabriele RicciardiDepartment of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
Emanuela GermanàDepartment of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
Valentina LulliDepartment of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Alessandra BoeCore Facilities, Istituto Superiore Di Sanità, Rome, Italy.
Mauro BiffoniDepartment of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Giovanna Marziali *Department of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Roberto Pallini *Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Lucia Ricci-Vitiani *Department of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy. lucia.riccivitiani@iss.it.

Funding

Associazione Italiana per la Ricerca sul Cancro IG2021 n.26515Ministero dell'Istruzione, dell'Università e della Ricerca PNC0000001
6 · The paper itself

Abstract

Glioblastomas (GBMs) are highly vascularized cancers. Transdifferentiation of GBM stem-like cells (GSCs) into GSC-derived endothelial cells (GdECs) contributes to GBM neovascularization. To dissect the molecular mechanisms and the signaling pathways underlying GSC contribution to tumor vascularization, we identified a three miRNA signature able to discriminate GSCs from GdECs by regulating different signaling pathways. DUSP8 resulted as the common target of the miRNA signature identified and is negatively regulated by miR-1825. DUSP8 is emerging as a critical negative regulator MAPKs pathway and is involved in cell oxidative stress response and apoptosis, as well as, in several diseases, including cancer. In GBM patients, DUSP8 and miR-1825 expression are inversely correlated and DUSP8 down-regulation is significantly associated with higher microvascular density and poor overall survival. Exploring the impact of DUSP8 in GSC transdifferentiation, we demonstrated that DUSP8 down-regulation interferes with MAPK pathway and affects soluble factor release. In vitro DUSP8 modulation experiments showed that DUSP8 enforced expression impairs GdEC ability to form tube-like structures. Gene expression variations induced by DUSP8 modulation affect transcripts associated with EMT pathway, confirming that DUSP8 shutdown and, therefore, the activation of MAPK pathway, is mandatory to GSC transdifferentiation. In vivo experiments demonstrated that both DUSP8 enforced expression and silencing dramatically affect gliomagenesis. Dissecting the molecular mechanisms underlying the contribution of GSCs to tumor angiogenesis might represent a chance to develop new and more efficient antiangiogenic therapeutic protocols for GBM treatment. Our findings provide a strong rationale to develop therapeutic strategies based on modulation of DUSP8 for GBM treatment.

Indexed as

Brain NeoplasmsDual-Specificity PhosphatasesGlioblastomaMitogen-Activated Protein Kinase PhosphatasesNeoplastic Stem CellsNeovascularization, PathologicAnimalsCell Line, TumorCell TransdifferentiationEndothelial CellsGene Expression Regulation, NeoplasticHumansMiceMicroRNAsDual-Specificity PhosphatasesMicroRNAsMitogen-Activated Protein Kinase PhosphatasesDUSP8Endothelial transdifferentiationGlioblastomaGlioblastoma Stem-like cellsMAPKsMiR-1825

Identifiers

PMID41029387
PMCPMC12486788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.